-
摘要: 头颈部鳞癌是以转移和局部侵袭为特征的恶性肿瘤，手术及放疗后复发率高，疾病预后及患者生存质量差。近年来，程序性死亡分子-1（programmed death-1，PD-1）抑制剂被新版美国国立综合癌症网络（NCCN）指南推荐用于治疗复发、不可切除和转移性头颈部鳞癌，其疗效引人瞩目。PD-1单抗为铂类化疗难治性的晚期头颈部鳞癌患者提供了新的治疗手段，降低术后功能丧失的风险，实现改善患者生存质量的目的。本文就免疫检查点PD-1/程序性细胞死亡分子配体-1（programmed death-ligand 1，PD-L1）的结构、作用机制和其抑制剂在治疗头颈部鳞癌中的研究进展等方面进行综述。
-
关键词:
- 头颈部鳞状细胞癌 /
- 程序性死亡分子-1 /
- 程序性细胞死亡分子配体-1 /
- 免疫检查点抑制剂
Abstract: Head and neck squamous cell carcinoma (HNSCC) is a kind of malignant tumor characterized by metastasis and local invasion. Its recurrence rate is high after surgery and radiotherapy, and the prognosis and quality of life are poor. In recent years, programmed death- 1 (PD-1) inhibitors have been recommended in National Comprehensive Cancer Network (NCCN) guidelines for the treatment of recurrent, unresectable, and metastatic HNSCC, and their efficacy has been remarkable. PD-1 inhibitors constitute a new treatment for the patients with advanced HNSCC who are refractory to platinum-based chemotherapy and can increase the probability of surgical resection, reduce the risk of postoperative dysfunction, and improve the survival and quality of life. This article reviews the structure and mechanism of the PD-1/PD-L1 immunocheckpoint, as well as research progress on its inhibitors in the treatment of HNSCC. -
表 1 抗PD-1治疗的HNSCC临床试验
表 2 抗PD-L1治疗的HNSCC临床试验
-
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. doi: 10.3322/caac.21492 [2] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):E359-E86. doi: 10.1002/ijc.29210 [3] Ferris, RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer[J]. Clin Cancer Res, 2006, 12(13):3890-3895. doi: 10.1158/1078-0432.CCR-05-2750 [4] Rasha Abu Eid. Advances in head and neck cancer immunology and immunotherapy[J]. Front Oncol, 2019, 19(9):172. https://www.ncbi.nlm.nih.gov/pubmed/30941315 [5] Ferris RL, Blumenschein Jr G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016, 375(19):1856-1867. doi: 10.1056/NEJMoa1602252 [6] Adelstein D, Gillison ML, Pfister DG, et al. NCCN guidelines insights:head and neck cancers, version 2.2017[J]. J Natl Compr Canc Netw, 2017, 15(6):761-770. doi: 10.6004/jnccn.2017.0101 [7] Ohaegbulam KC, Assal A, Lazar-Molnar E, et al. Human cancer immunotherapy with antibodies to the PD- 1 and PD- L1 pathway[J]. Trends Mol Med, 2015, 21(1):24-33. doi: 10.1016/j.molmed.2014.10.009 [8] OK CY, Young KH. Targeting the programmed death-1 pathway in lymphoid neoplasms[J]. Cancer Treat Rev, 2017, 54:99-109. doi: 10.1016/j.ctrv.2017.01.009 [9] Woroniecka K, Chongsathidkiet P, Rhodin K, et al. T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma[J]. Clin Cancer Res, 2018, 24(17):4175-4186. doi: 10.1158/1078-0432.CCR-17-1846 [10] Lin YM, Sung WW, Hsieh MJ, et al. High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma[J]. PLoS One, 2015, 10(11):e0142656. doi: 10.1371/journal.pone.0142656 [11] Yu GT, Bu LL, Huang CF, et al. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPalpha axis in HPV negative head and neck squamous cell carcinoma[J]. Oncotarget, 2015, 6(39):42067-42080. doi: 10.18632/oncotarget.5955 [12] Kansy BA, Concha-Benavente F, Srivastava RM, et al. PD-1 status in CD8(+) T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer[J]. Cancer Res, 2017, 77(22):6353-6364. doi: 10.1158/0008-5472.CAN-16-3167 [13] Borch TH, Donia M, Andersen MH, et al. Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies[J]. Drug Discov Today, 2015, 20(9):1127-1134. doi: 10.1016/j.drudis.2015.07.003 [14] Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic Anti-PD- L1 monoclonal antibody[J]. Cancer Immunol Res, 2015, 3(9):1052-1062. doi: 10.1158/2326-6066.CIR-14-0191 [15] Deng R, Cassady K, Li X, et al. B7H1/CD80 interaction augments PD-1- dependent T cell apoptosis and ameliorates graft-versus-host disease[J]. J Immunol, 2015, 194(2):560-574. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=df21019ca445ef95312bdf9037c8711a [16] Zandberg DP, Algazi AP, Jimeno A, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma:Results from a single-arm, phase Ⅱ study in patients with >/=25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy[J]. Eur J Cancer, 2019, 107:142-152. doi: 10.1016/j.ejca.2018.11.015 [17] Ran X, Yang K. Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer:current status and future perspectives[J]. Drug Des Devel Ther, 2017, 11:2007-2014. doi: 10.2147/DDDT.S140687 [18] Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker- unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma:results from the phase Ⅰb KEYNOTE-012 expansion cohort[J]. J Clin Oncol, 2016, 34(32):3838-3845. doi: 10.1200/JCO.2016.68.1478 [19] Routy B, Gopalakrishnan V, Daillere R, et al. The gut microbiota influences anticancer immunosurveillance and general health[J]. Nat Rev Clin Oncol, 2018, 15(6):382-396. doi: 10.1038/s41571-018-0006-2 [20] Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer:results from a single-arm, phase Ⅱ study[J]. J Clin Oncol, 2017, 35(14):1542-1549. doi: 10.1200/JCO.2016.70.1524 [21] Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head- and- neck squamous cell carcinoma (KEYNOTE- 040):a randomised, open-label, phase 3 study[J]. Lancet, 2019, 393(10167):156- 167. doi: 10.1016/S0140-6736(18)31999-8 [22] Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE- 048):a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7 [23] Ferris RL, Licitra L, Fayette J, et al. Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck:efficacy and safety in checkmate 141 by prior cetuximab use[J]. Clin Cancer Res, 2019, 25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944 [24] Haddad R, Concha-Benavente F, Blumenschein Jr G, et al. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141:A subgroup analysis of a randomized phase 3 clinical trial[J]. Cancer, 2019, 125(18):3208-3218. doi: 10.1002/cncr.32190 [25] Singer S. Quality of life after nivolumab treatment for head and neck cancer[J]. Lancet Oncol, 2017, 18(8):993-994. doi: 10.1016/S1470-2045(17)30463-1 [26] Harrington KJ, Ferris RL, Blumenschein Jr G, et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141):health-related quality-of-life results from a randomised, phase 3 trial[J]. Lancet Oncol, 2017, 18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7 [27] Nishikawa D, Suzuki H, Koide Y, et al. Prognostic markers in head and neck cancer patients treated with nivolumab[J]. Cancers (Basel), 2018, 10(12):466. doi: 10.3390/cancers10120466 [28] Colevas AD, Bahleda R, Braiteh F, et al. Safety and clinical activity of atezolizumab in head and neck cancer:results from a phase I trial[J]. Ann Oncol, 2018, 29(11):2247-2253. doi: 10.1093/annonc/mdy411 [29] Bernard-Tessier A, Bonnet C, Lavaud P, et al. Atezolizumab Tecentriq(R):Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma[J]. Bull Cancer, 2018, 105(2):140-145. doi: 10.1016/j.bulcan.2017.10.030 [30] Garassino MC, Cho BC, Kim JH, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC):an open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X [31] Segal NH, Ou SI, Balmanoukian A, et al. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma:results from a phase Ⅰ/Ⅱ expansion cohort[J]. Eur J Cancer, 2019, 109:154-161. doi: 10.1016/j.ejca.2018.12.029 [32] Siu LL, Even C, Mesia R, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD- L1- Low/negative recurrent or metastatic HNSCC:the phase 2 condor randomized clinical trial[J]. JAMA Oncol, 2019, 5(2):195-203. doi: 10.1001/jamaoncol.2018.4628 [33] Bahig H, Aubin F, Stagg J, et al. Phase Ⅰ/Ⅱ trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma[J]. BMC Cancer, 2019, 19(1):68. doi: 10.1186/s12885-019-5266-4 [34] Yearley JH, Gibson C, Yu N, et al. PD- L2 expression in human tumors:relevance to anti-PD-1 therapy in cancer[J]. Clin Cancer Res, 2017, 23(12):3158-3167. doi: 10.1158/1078-0432.CCR-16-1761 -
点击查看大图
表(2)
计量
- 文章访问数: 158
- HTML全文浏览量: 16
- PDF下载量: 45
- 被引次数: 0
下载:
